STOCK TITAN

Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Arvinas, a clinical-stage biotechnology firm listed on Nasdaq under the symbol ARVN, announced its participation in the Goldman Sachs 43rd Annual Global Healthcare Conference scheduled for June 13 at 4:20 p.m. ET. The event will feature a fireside chat with the company's management in Rancho Palos Verdes, California. A live audio webcast will be available on the company's website. Arvinas focuses on developing therapies that degrade disease-causing proteins, utilizing its proprietary PROTAC® technology, with ongoing clinical programs targeting prostate and breast cancer.

Positive
  • None.
Negative
  • None.

NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Monday, June 13 at 4:20 p.m. ET / 1:20 p.m. PT in Rancho Palos Verdes, Calif.

A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts

Investors:
Jeff Boyle
347-247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
203-584-0307
Kirsten.Owens@arvinas.com


FAQ

When is Arvinas participating in the Goldman Sachs Healthcare Conference?

Arvinas will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 4:20 p.m. ET.

How can I listen to the Arvinas presentation at the conference?

A live audio webcast of Arvinas' presentation will be available on the company's website during the event.

What is the focus of Arvinas' research and development?

Arvinas is focused on creating therapies that degrade disease-causing proteins using its PROTAC® technology.

What clinical-stage programs does Arvinas have?

Arvinas has three investigational clinical-stage programs targeting metastatic castration-resistant prostate cancer and ER+/HER2- breast cancer.

Where is the Goldman Sachs Healthcare Conference being held?

The Goldman Sachs Healthcare Conference is being held in Rancho Palos Verdes, California.

Arvinas, Inc

NASDAQ:ARVN

ARVN Rankings

ARVN Latest News

ARVN Stock Data

1.22B
62.43M
7.22%
109.24%
12.43%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN